We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Accepts Apotex’s Pegfilgrastim Application as Biosimilars Movement Slowly Gains Steam
FDA Accepts Apotex’s Pegfilgrastim Application as Biosimilars Movement Slowly Gains Steam
Apotex’s application for a biosimilar version of Amgen’s chemotherapy Neulasta has been accepted by the FDA, one of several recent signs that regulatory movement on approving the therapies is gaining momentum.